When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics? - Wikidata - wikimedia - TriplyDB

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

http://www.wikidata.org/entity/Q51460131

about

Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines.Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.

P2860

Q38676164-D8C650FB-AFCD-412A-8A2A-E1DEA81A2DCD Q46611022-24754882-4884-4F5C-B03A-70C4AB167808

P2860

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

http://www.wikidata.org/entity/Q51460131

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@en

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@nl

type

label

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@en

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@nl

prefLabel

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@en

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@nl

P1433

Q51460131-305DC6AF-2CE0-405D-91DA-D6D4AEA73AA1

P1476

Q51460131-BA3FBF11-1DDA-4542-8129-FEA3AC7615DB

P2093

Q51460131-34C2711D-9A74-4F5B-831D-C59D79900BBA

Q51460131-35C6225F-26CF-4563-89A0-1D4B7A0260AF

Q51460131-BA583611-EE91-4287-B900-E92AEFFA5F6F

P2860

Q51460131-00C28C6C-6068-4BF6-8E27-8103F8F56D29

Q51460131-05373F9D-7BCB-4ECA-994C-9318EB4C8819

Q51460131-06EDBED3-431D-47BD-A4B4-202DB14ED029

Q51460131-07D2CE76-476D-4C69-A67E-3E15D7CAD798

Q51460131-0E98E8CE-BAF8-4386-B3A6-A8F6B7D2397F

Q51460131-1156D5DB-E705-4A6E-BE38-AF760035CB4F

Q51460131-1466D111-D945-4CB5-9090-F1703B53C513

Q51460131-1895922F-C481-443F-B172-CCF6F9120F69

Q51460131-1C8CBC6E-AE3B-4EF8-A0EE-E65D4F481A9A

Q51460131-231D7DD1-95E3-4EFC-A9A9-348DD4902907

P304

Q51460131-43855AD6-274C-4226-BC05-C21B9222F52D

P31

Q51460131-EA4F7315-9EF0-4CC5-8080-B7F7FE67633B

P356

Q51460131-FBC38146-6C5A-4770-904D-BB2B2D42501B

P433

Q51460131-5E08C5CA-7745-45D5-AE84-1B4D2F76502D

P478

Q51460131-CF98EE67-516B-4FBB-B87E-F404DE0A5DBB

P577

Q51460131-1AF147BD-0148-4F59-B173-FE5F267B5876

P698

Q51460131-738D5CD7-1F3F-490F-85EA-DD910AD86404

P932

Q51460131-8C8F5B0F-EF91-4A68-A2FB-32EEA8F10D53

P356

P1433

Drug Metabolism and Disposition

P1476

When Is It Important to Measure Unbound Drug in Evaluating Nanomedicine Pharmacokinetics?

@en

P2093

David M Stevens

http://www.w3.org/2001/XMLSchema#string

Marilyn N Martinez

http://www.w3.org/2001/XMLSchema#string

Stephan T Stern

http://www.w3.org/2001/XMLSchema#string

P2860

A holistic approach to targeting disease with polymeric nanoparticles

The big picture on nanomedicine: the state of investigational and approved nanomedicine products

Macromolecular therapeutics in cancer treatment: the EPR effect and beyond

Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

Measurement of fraction unbound paclitaxel in human plasma.

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

Changes in plasma protein binding have little clinical relevance.

P304

1934-1939

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/DMD.116.073148

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27670412

http://www.w3.org/2001/XMLSchema#string

P932

5118636

http://www.w3.org/2001/XMLSchema#string